OBJECTIVE: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). METHODS: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. RESULTS: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. CONCLUSIONS: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
OBJECTIVE: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). METHODS: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. RESULTS: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. CONCLUSIONS: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
Authors: Jennifer Ngolab; Michael Donohue; Alison Belsha; Jennifer Salazar; Paula Cohen; Sandhya Jaiswal; Veasna Tan; Devon Gessert; Shaina Korouri; Neelum T Aggarwal; Jessica Alber; Ken Johnson; Gregory Jicha; Christopher van Dyck; James Lah; Stephen Salloway; Reisa A Sperling; Paul S Aisen; Michael S Rafii; Robert A Rissman Journal: Alzheimers Dement (Amst) Date: 2021-08-17